Ardelyx, Inc. Q3 2024 Earnings Call

Ardelyx, Inc. (ticker: NASDAQ:ARDX) held its Q3 2024 Earnings Call on October 31, 2024, showcasing strong performance with significant growth in net sales for its two key products, IBSRELA and XPHOZAH. CEO Mike Raab emphasized the potential of IBSRELA to become a blockbuster drug for IBS-C patients and the increasing adoption of XPHOZAH among dialysis patients.

Despite facing coverage challenges with Medicare for XPHOZAH, the company reported a total revenue of $98.2 million for the quarter, a substantial increase from the previous year. The company's net losses have narrowed, and it maintains a robust cash position, indicating a positive outlook for continued growth.

Key Takeaways

• IBSRELA and XPHOZAH show strong sales growth, with IBSRELA aiming for $145-$150 million in U.S. net sales for 2024.
• Ardelyx is advocating for the Kidney Patient Act and has initiated legal action against CMS over Medicare coverage for XPHOZAH.
• The company reported a 39% quarter-over-quarter increase in XPHOZAH's net sales, reaching $51.5 million.
• Total revenue for Q3 2024 was $98.2 million, up from $56.4 million in Q3 2023, with net losses narrowing to approximately $800,000.
• Ardelyx ended the quarter with a strong cash position of $190.4 million, with a pro forma balance exceeding $240 million.

Company Outlook

• Sales guidance for IBSRELA is expected early next year, while XPHOZAH's guidance remains uncertain due to Medicare coverage developments.
• The company has completed the expansion of the IBSRELA sales team, with full effects anticipated in early 2025.
• Ardelyx is monitoring potential legal actions related to its products.

Bearish Highlights

• Medicare coverage for XPHOZAH is challenged by the removal of Part D coverage for oral therapies starting January 1, 2025.
• Uncertainty remains for XPHOZAH's sales guidance timeline due to ongoing Medicare developments.

Bullish Highlights

• IBSRELA is well-positioned for growth with a projected $145-$150 million in U.S. net sales for 2024.
• XPHOZAH's net sales have grown by 39% from the previous quarter, indicating strong demand.
• Legislative support for the Kidney Patient Act is increasing, which could positively impact Medicare coverage issues.

Misses

• Ardelyx faces uncertainties with Medicare Part D coverage, which may impact future sales projections.
• Gross to net deductions for IBSRELA are around 30%, with expectations of increased gross spend as insurance plans reset in 2025.

Q&A Highlights

• The company's focus is on ensuring patient access to XPHOZAH and IBSRELA, with ArdelyxAssist aiding in prescription adjudication.
• A court decision on the APA lawsuit against CMS is expected by the end of the year.
• Positive feedback from physicians at the ASN meeting reflects well on XPHOZAH's utilization and effectiveness.

Ardelyx continues to navigate the complexities of the healthcare market, focusing on patient care and commercial success. The company's commitment to improving outcomes for patients suffering from IBS-C and hyperphosphatemia is evident in its strong financial results and proactive approach to addressing access barriers. Despite the uncertainties, Ardelyx's leadership remains confident in the company's strategy and its ability to sustain growth and maximize shareholder value.

InvestingPro Insights

Ardelyx's recent financial performance aligns with several key metrics and insights from InvestingPro. The company's impressive revenue growth is reflected in the InvestingPro data, which shows a remarkable 227.86% quarterly revenue growth in Q2 2024. This significant increase supports the strong sales performance of IBSRELA and XPHOZAH mentioned in the earnings call.

An InvestingPro Tip highlights that analysts anticipate sales growth in the current year, consistent with the company's positive outlook and the projected sales figures for IBSRELA. Additionally, the tip indicating that six analysts have revised their earnings upwards for the upcoming period suggests growing confidence in Ardelyx's financial trajectory.

Despite the company's strong revenue growth, InvestingPro data reveals that Ardelyx is not yet profitable, with an operating income margin of -28.05% in the last twelve months as of Q2 2024. This aligns with the article's mention of narrowing net losses, indicating that while the company is moving in the right direction, it still faces challenges in achieving profitability.

The company's robust cash position of $190.4 million, as reported in the article, is supported by an InvestingPro Tip noting that Ardelyx's liquid assets exceed short-term obligations. This financial stability is crucial as the company continues to invest in growth and navigate regulatory challenges.

Investors should note that Ardelyx is trading at a high Price / Book multiple of 9.4, according to InvestingPro data. This valuation may reflect market optimism about the company's future prospects, particularly given the strong sales growth of its key products.

For those interested in a deeper analysis, InvestingPro offers eight additional tips for Ardelyx, providing a more comprehensive view of the company's financial health and market position.

Full Transcript – Ardelyx Inc (ARDX) Q3 2024

Operator: Good afternoon, ladies and gentlemen and welcome to the Ardelyx Third Quarter 2024 Earnings Call. Our host for today's call is Caitlin Lowie, Vice President of Corporate Communications and Investor Relations at Ardelyx…

Caitlin Lowie: Thank you. Good afternoon and welcome to our third quarter 2024 financial results call. During this call, we will refer to the press release issued earlier today available on the Investors section of the company's website at ardelyx.com. During this call, we will be making forward-looking statements that are subject to risks and uncertainties. Our actual results may differ materially from those described. We encourage you to review the risk factors in our most recent quarterly report on Form 10-Q, which was filed today and can be found on our website at ardelyx.com. While we may elect to update these forward-looking statements in the future, we specifically disclaim any obligation to do so even if our views change…

Michael Raab: Good afternoon, everyone and thank you for spending part of your Halloween with us this year. It was a busy third quarter and Eric, Justin, and I will bring you up to speed on the latest developments and provide some insight into what you can expect in the months ahead…

Justin Renz: Thank you, Eric and it's great to have you on these calls and at Ardelyx…

Michael Raab: Thank you, Justin and Eric. The third quarter was another exceptional one. We focused on executing our key priorities, including maintaining our commercial momentum, supporting efforts to preserve patient access to XPHOZAH, strengthening our cash position, and envisioning the next phase of growth for the company. The result is another quarter of excellent progress, consistent growth, and most importantly, doing what is right for the patients we serve. Because we believe that if we serve patients, we will serve shareholders…

Operator: This concludes our question-and-answer session. I would like to turn the conference back over to President and CEO, Mike Raab, for any closing remarks.

Michael Raab: Thank you, everyone, for joining us this evening. As always, we remain focused on our priorities and will provide information updates when we can. In the meantime, we remain steadfast in our commitment to patients and to maintaining our commercial momentum. With that, we can close the call. Thank you, operator.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.